We are the Cancer Immunotherapy Endowment Fund (CIEF), a small independent fund supporting the translation of MBTA immunotherapy from preclinical research into clinical trials.
**What is MBTA?**
MBTA (Mannan-BAM + TLR agonists + anti-CD40 antibody) is an intratumoral immunotherapy that activates the innate immune system to recognize and destroy tumor cells, subsequently engaging adaptive immunity to eliminate metastases and generate long-term immune memory.
In preclinical mouse models, MBTA achieves:
- Complete remission in 80%+ of animals with advanced tumors
- Suppression of metastases
- Resistance to tumor recurrence
- Efficacy across 7 tumor types: melanoma, sarcoma, pancreatic adenocarcinoma, colorectal cancer, pheochromocytoma, breast cancer, glioblastoma
This is not a fringe idea. The research is backed by 20 peer-reviewed publications (2014–2025) in journals including Cancer Letters, Advanced Science, and Frontiers in Endocrinology, with contributions from teams at the NIH.
**What’s the bottleneck?**
The science is advancing. The bottleneck is funding and awareness. Translating a therapy to clinical trials requires GMP-grade production, toxicology testing, and three phases of clinical trials — a process that typically takes 12–14 years and costs tens of millions of dollars.
We are a small team. The researchers are focused on research. We lack someone who can translate this work for non-specialist audiences, build credibility with potential donors, and help us grow.
**What we’re looking for**
One person — anywhere in the world — willing to take on science communication and fundraising for this project as a pro-bono or low-cost mission. Ideally someone with:
- Experience in PR, communications, or fundraising (science/health/nonprofit background preferred)
- Ability to communicate with both scientists and donors
- Comfort working with a small remote team and AI tools
- Personal motivation — impact over income
**Why this might be a high-impact opportunity**
If MBTA works in humans at even a fraction of its preclinical efficacy, the potential impact is enormous. Cancer kills ~10 million people per year globally. Helping move a promising therapy closer to clinical trials — by bridging the funding and awareness gap — could be one of the higher-leverage interventions available to a skilled communicator.
We are not claiming this will work. Preclinical results often don’t translate. But the evidence is strong enough that we believe it deserves a serious shot.
**Learn more**
- Science: cancerimmunotherapy.cz
- Fund: cancerimmunotherapyfund.com
If you’re interested or know someone who might be, please reach out or comment below.
